Annexon, Inc.
ANNXHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Valued at $888.0M, ANNX is a small-cap name in its sector. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Market Cap
$888.0M
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-5.87
EPS (TTM)
$-1.20
EPS (Fwd)
$-0.92
ROE
-87.6%
ROA
-45.3%
Cash
$225.0M
Total Debt
$25.4M
Free CF
-$107.3M
52W Change
155.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $225.0M in cash comfortably exceeding the $25.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$107.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -87.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Annexon, Inc. and its sector.